ProstAtak is a gene therapy commercialized by Candel Therapeutics, with a leading Phase III program in Prostate Cancer. According to Globaldata, it is involved in 11 clinical trials, of which 5 were completed, and 6 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of ProstAtak’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for ProstAtak is expected to reach an annual total of $217 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

ProstAtak Overview

aglatimagene besadenovec is under development for the treatment of non-small cell lung cancer, high grade glioma. malignant glioma, pediatric malignant glioma including glioblastoma multiforme, recurrent glioblastoma multiforme, anaplastic astrocytoma and recurrent ependymomas, advanced non-metastatic pancreatic adenocarcinoma and prostate cancer. The therapeutic drug candidate consists of (AdV-tk) adenovirus-mediated expression of herpes simplex virus thymidine kinase and valacyclovir in combination with radiation therapy. AdV-tk is administered as intra-tumoral injection and valacyclovir is administered orally. It is developed based on the gene mediated cytotoxic immunotherapy (GMCI) technology.

Candel Therapeutics Overview

Candel Therapeutics, formerly Advantagene, is a biopharmaceutical company. It manufactures, develops, and tests cancer immunotherapy drugs and gene-based biologics. Candel Therapeutics offers CAN-2409 and CAN-3110, for the treatment of a broad range of solid tumor indications. It is focused on developing oncolytic viral immunotherapies for the treatment of cancer patients. The company’s oncolytic viral immunotherapy platforms use genetically engineered viruses to induce immunogenic death through viral-mediated cytotoxicity in cancer cells. Its products, CAN-3110 and CAN-2409 are used in the treatment of prostate cancer, brain cancer, pancreatic cancer, lung cancer, malignant pleural effusion, and mesothelioma. Candel Therapeutics is headquartered in Needham, Massachusetts, the US.

The operating loss of the company was US$25.7 million in FY2021, compared to an operating loss of US$13.8 million in FY2020. The net loss of the company was US$36.1 million in FY2021, compared to a net loss of US$17.7 million in FY2020.

For a complete picture of ProstAtak’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.